Panion & Bf Biotech Inc. (TPE:1760)
Taiwan · Delayed Price · Currency is TWD 58.10
-0.20 (-0.34%)
Aug 19, 2026, 1:30 PM CST
Panion & Bf Biotech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2,109 | 2,063 | 2,030 | 1,882 | 2,399 | 1,901 | |
Revenue Growth | 4.99% | 1.66% | 7.85% | -21.54% | 26.16% | 21.20% |
Cost of Revenue | 994.57 | 946.54 | 959.37 | 907.48 | 1,080 | 989.07 |
Gross Profit | 1,115 | 1,117 | 1,070 | 974.4 | 1,319 | 912.14 |
Selling, General & Admin | 628.05 | 612.69 | 618.22 | 601.58 | 656.06 | 587 |
Research & Development | 167.9 | 195.46 | 236.88 | 217.04 | 248.5 | 157.71 |
Other Operating Expenses | - | - | 9.84 | - | - | - |
Operating Expenses | 797.69 | 809 | 864.61 | 817.57 | 904.63 | 746.8 |
Operating Income | 316.96 | 307.85 | 205.67 | 156.83 | 413.96 | 165.34 |
Interest Expense | -14.02 | -14.34 | -15.02 | -11.36 | -7.59 | -14.68 |
Interest & Investment Income | 3.3 | 4.19 | 10.46 | 11.19 | 4.77 | 7.02 |
Earnings From Equity Investments | 0.89 | 2.65 | -8.44 | -14.02 | -8.18 | -12.17 |
Currency Exchange Gain (Loss) | -10.8 | -10.8 | 11.95 | -2.97 | -0.32 | -3.07 |
Other Non Operating Income (Expenses) | 23.01 | 4.28 | 10.77 | 21.33 | 17.55 | 33.84 |
EBT Excluding Unusual Items | 319.34 | 293.82 | 215.39 | 161.01 | 420.2 | 176.28 |
Gain (Loss) on Sale of Investments | 0.24 | 0.24 | 1.46 | 7.5 | -93.68 | 6.72 |
Gain (Loss) on Sale of Assets | -0.13 | -0.13 | -0.1 | -0.38 | 6.28 | -0.44 |
Other Unusual Items | 0.11 | 0.11 | 0.69 | 0.58 | 0.61 | 0.08 |
Pretax Income | 319.56 | 294.04 | 217.44 | 168.71 | 333.41 | 182.65 |
Income Tax Expense | 104.73 | 103.87 | 92.91 | 91.49 | 151.06 | 78.25 |
Net Income | 214.83 | 190.17 | 124.52 | 77.22 | 182.35 | 104.4 |
Net Income to Common | 214.83 | 190.17 | 124.52 | 77.22 | 182.35 | 104.4 |
Net Income Growth | 69.51% | 52.72% | 61.26% | -57.65% | 74.66% | 274.19% |
Shares Outstanding (Basic) | 86 | 86 | 86 | 86 | 86 | 79 |
Shares Outstanding (Diluted) | 86 | 86 | 86 | 86 | 86 | 79 |
Shares Change | -0.15% | 0.11% | 0.01% | -0.04% | 8.32% | 3.18% |
EPS (Basic) | 2.51 | 2.22 | 1.45 | 0.90 | 2.13 | 1.32 |
EPS (Diluted) | 2.50 | 2.21 | 1.45 | 0.90 | 2.12 | 1.32 |
EPS Growth | 70.12% | 52.41% | 61.11% | -57.55% | 60.78% | 266.26% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 196.43 | 161.23 | 165.49 | -3.81 | 291.23 | 231.22 |
Free Cash Flow Per Share | 2.29 | 1.88 | 1.93 | -0.04 | 3.39 | 2.92 |
Dividend Per Share | 2.000 | 2.000 | 1.800 | 1.500 | 2.000 | 1.500 |
Dividend Growth | 11.11% | 11.11% | 20.00% | -25.00% | 33.33% | 114.29% |
Gross Margin | 52.85% | 54.13% | 52.73% | 51.78% | 54.97% | 47.98% |
Operating Margin | 15.03% | 14.92% | 10.13% | 8.33% | 17.26% | 8.70% |
Profit Margin | 10.18% | 9.22% | 6.13% | 4.10% | 7.60% | 5.49% |
Free Cash Flow Margin | 9.31% | 7.81% | 8.15% | -0.20% | 12.14% | 12.16% |
EBITDA | 429.36 | 422.29 | 341.73 | 298.19 | 546.26 | 275.7 |
EBITDA Margin | 20.36% | 20.47% | 16.84% | 15.85% | 22.77% | 14.50% |
D&A For EBITDA | 112.4 | 114.45 | 136.06 | 141.36 | 132.29 | 110.36 |
EBIT | 316.96 | 307.85 | 205.67 | 156.83 | 413.96 | 165.34 |
EBIT Margin | 15.03% | 14.92% | 10.13% | 8.33% | 17.26% | 8.70% |
Effective Tax Rate | 32.77% | 35.32% | 42.73% | 54.23% | 45.31% | 42.84% |